DEF: Oruka Therapeutics Announces Annual Stockholders Meeting and Director Nominations

Oruka Therapeutics will hold its annual stockholders meeting virtually on June 2, 2025, to vote on director elections, auditor ratification, executive compensation, and the frequency of future compensation votes.

Summary

• Oruka Therapeutics, Inc. is holding its Annual Meeting of Stockholders virtually on June 2, 2025, at 8:00 a.m. Pacific Time.
• Stockholders of record as of April 7, 2025, are entitled to vote on the election of two Class I directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, an advisory vote on executive compensation, and an advisory vote on the frequency of future executive compensation votes.
• The Board recommends voting for the election of Carl Dambkowski and Peter Harwin as directors, for the ratification of PricewaterhouseCoopers LLP, for the approval of executive compensation, and for holding advisory votes on executive compensation every year.
• The company completed its acquisition of Pre-Merger Oruka on August 29, 2024, and changed its name from ARCA biopharma, Inc. to Oruka Therapeutics, Inc.
• In 2024, PwC billed $1,928,000 for audit fees and $2,000 for other fees, totaling $1,930,000.
• KPMG was dismissed as the independent registered public accounting firm on August 30, 2024, and PwC was appointed on the same date.
• The company's executive compensation program aims to attract and retain talented executives, align their interests with stockholders, and motivate them to manage the business effectively.
• The Board recommends holding say-on-pay votes annually to ensure regular feedback on executive compensation.
• The company's governance structure includes a classified board, supermajority voting requirements, plurality voting for directors, and restrictions on stockholders calling special meetings or acting by written consent.
• The Board has determined that all directors except Lawrence Klein are independent.
• The company has an active role in overseeing risk management, with committees responsible for overseeing specific areas of risk.
• The Board met three times since the Merger.
• Non-employee directors are eligible for cash and equity compensation, with annual cash retainers of $40,000 and additional retainers for committee chairs and members.
• In connection with the company's annual meeting of stockholders, each member of the Board will receive an annual grant of stock options to purchase 17,500 shares of common stock.
• The company has offer letters with its executive officers that provide for certain payments and benefits upon termination of employment or a change in control.
• The company maintains a Compensation Recoupment (Clawback) Policy.
• The company generally grants annual equity awards, including stock options, in January of each year.
• The company's largest stockholders include entities affiliated with Fairmount Funds Management LLC (19.99%), FMR LLC (14.86%), and Venrock Healthcare Capital Partners (11.08%).
• The company has entered into agreements with Paragon and Paruka for the development of antibodies, including ORKA-001 and ORKA-002.
• The company has adopted a written related person transactions policy.
• Stockholders who wish to submit proposals for the 2026 Annual Meeting must do so by December 19, 2025.
• The company will provide a free copy of its Annual Report on Form 10-K to any stockholder upon request.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which generally presents information in a neutral tone. The company is seeking approval for routine matters, and the Board's recommendations are clearly stated. The company has recently completed a merger and is focused on developing novel biologics, which is a positive sign for future growth.

Positives

• The Board recommends holding say-on-pay votes annually to ensure regular feedback on executive compensation.
• The company has an active role in overseeing risk management, with committees responsible for overseeing specific areas of risk.
• The company has adopted a written related person transactions policy.

Negatives

• The company's governance structure includes supermajority voting requirements, plurality voting for directors, and restrictions on stockholders calling special meetings or acting by written consent, which could limit stockholder influence.

Risks

• The Proxy Statement may contain forward -looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions.
• The company faces extreme stock price and volume fluctuations that are often unrelated or disproportionate to our operating performance.

Future Outlook

The company aims to develop novel biologics designed to set a new standard for the treatment of chronic skin diseases, offering patients high rates of complete disease clearance with infrequent dosing.

Industry Context

Oruka Therapeutics operates in the biotechnology industry, which is characterized by high risk, long development timelines, and significant capital requirements. The company's focus on novel biologics for chronic skin diseases aligns with the growing demand for innovative treatments in this therapeutic area.

Comparison to Industry Standards

• The peer group established by Pre-Merger Oruka includes companies such as Apogee Therapeutics, Astria Therapeutics, and Kymera Therapeutics, which are all U.S.-based, pre-clinical or early clinical biopharma companies with a similar therapeutic focus and market capitalization ranging from $250 million to $2 billion.
• Executive compensation practices are benchmarked against this peer group to ensure competitiveness and alignment with industry standards.

Related Party Transactions

• The company has entered into agreements with Paragon and Paruka for the development of antibodies, including ORKA-001 and ORKA-002.
• The company has adopted a written related person transactions policy.

Stakeholder Impact

• The outcome of the votes on director elections and executive compensation will impact the company's leadership and strategic direction.
• The company's focus on developing novel biologics for chronic skin diseases could benefit patients suffering from these conditions.
• The company's financial performance and stock price will be influenced by its ability to execute its business strategy and develop successful products.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting of Stockholders on June 2, 2025.
• The Board and its committees will review and consider the voting results when making future decisions regarding executive compensation and corporate governance.

Key Dates

Keywords

stockholders meeting, proxy statement, director election, executive compensation, auditor ratification, corporate governance, Oruka Therapeutics, PricewaterhouseCoopers, Fairmount Funds, FMR LLC, Venrock Healthcare, Paragon, ORKA-001, ORKA-002, biotechnology